Are you Dr. Johnsen?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 41 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
75 Mount Auburn St
Cambridge, MA 02138Phone+1 617-496-9506Fax+1 617-495-6059
Summary
- Dr. Alyssa Johnsen, MD is an internist in Cambridge, Massachusetts. She is currently licensed to practice medicine in Pennsylvania.
Education & Training
Brigham and Women's HospitalFellowship, Rheumatology, 2003 - 2007
Massachusetts General HospitalResidency, Internal Medicine, 2001 - 2003
Case Western Reserve University School of MedicineClass of 2001
Certifications & Licensure
PA State Medical License 2009 - 2016
Awards, Honors, & Recognition
- Fellow American College of Rheumatology
Publications & Presentations
PubMed
- 3 citationsCan switching to abatacept therapy in patients with rheumatoid arthritis on background methotrexate reverse TNF-inhibitor-induced antinuclear autoantibody/double-stran...Maya H Buch, Alyssa Johnsen, Michael Schiff
Clinical and Experimental Rheumatology. 2019-01-18 - 8 citationsImproved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trialVibeke Strand, Evo Alemao, T. Lehman, Alyssa Johnsen, Subhashis Banerjee
Arthritis Research & Therapy. 2018-12-06 - 14 citationsDevelopment of a Molecular Signature to Monitor Pharmacodynamic Responses Mediated by In Vivo Administration of GlucocorticoidsYanhua Hu, Julie Carman, Deborah A. Holloway, Selena Kansal, Li Fan
Arthritis & Rheumatology. 2018-07-12
Press Mentions
Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data at Psych Congress 2024October 28th, 2024- New Phase 3 First-in-Class TREMFYA® (Guselkumab) Data Show Durability of Joint Efficacy, Including Low Rates of Structural Damage Progression, and a Demonstrated Safety Profile in Adults with Active Psoriatic Arthritis (PsA)November 1st, 2021
- New Comprehensive Phase 3 Data Show First-in-Class TREMFYA® (Guselkumab) Provided Durable Improvements in Measures of Psoriatic Arthritis (PsA) Disease Activity Through Two YearsNovember 1st, 2021
- Join now to see all
